Labiotech.eu

More News! 6 Feb 2019

British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy

Orexia and Inexia, two new virtual companies spun out of Sosei Heptares, will develop drugs for neurological diseases such as narcolepsy with funding from Medicxi Ventures. The companies will develop drugs that activate two molecules called OX1 and OX2. These molecules act as receptors of orexin, a protein that regulates arousal, wakefulness and sleep. The […]

February 6, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

breast cancer metformin klefstrom checkpoint inhibitor thumbnail

News and Trends 6 Feb 2019

Combo of Immunotherapy and Diabetes Drug Could Beat Breast Cancer

A Finnish research group has combined two cancer drugs with the diabetes drug metformin, making mice with breast cancer survive for longer than when given the treatments individually. The combination therapy included metformin, which can inhibit tumor growth; the cancer drug venetoclax, which causes cancer cells to commit suicide; and a checkpoint inhibitor antibody, which […]

February 6, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Feb 2019

Engineered Chicken Eggs: The Future of Cheap Drug Production?

Scientists at the University of Edinburgh have produced high-quality human proteins in chicken eggs, a method that could be significantly cheaper than the current standard. The researchers engineered the DNA of chickens to make them produce human proteins in the egg white, from where they can be easily purified. In a study published on the […]

February 6, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

elypta renal cell carcinoma kidney blood cancer

News and Trends 4 Feb 2019

Swedish Biotech Receives EU Grant for High-Accuracy Kidney Cancer Test

The Swedish biotech Elypta has received a Horizon 2020 grant of €2.4M to fund a clinical trial of a blood and urine test that provides an accurate diagnosis of renal cell carcinoma. The clinical trial aims to validate Elypta’s technology as a monitoring tool in patients who have been treated for the kidney cancer renal […]

February 4, 2019 - 2 minutesmins - By Jonathan Smith

Startup Scout 1 Feb 2019

This Biotech Links the Gut Microbiome to Diseases Using Norwegian Poo

In Norway’s capital city of Oslo, the biotech Bio-Me can rapidly screen for specific gut bacteria, gathering data from thousands of Norwegian stool samples to link the gut microbiome to diseases. Mission: To rapidly screen thousands of stool samples from a Norwegian population study and link the gut microbiome with disease. Client companies will then […]

February 1, 2019 - 4 minutesmins - By Jonathan Smith

More News! 31 Jan 2019

Watch Strap Made of Recombinant Spider Silk Launches in Europe

Sold by the luxury brand Omega, the watch strap is made with spider silk proteins that are brewed by genetically engineered bacteria. Spider silk is known in the textile industry for its strength, resilience, flexibility and light weight. However, it is not possible to ‘farm’ spiders to produce their silk at an industrial scale. The […]

January 31, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

CRISPR wageningen netherlands gluten wheat

News and Trends 31 Jan 2019

CRISPR Gene Editing Could Make Gluten Safe for Celiacs

A Dutch research group is using the gene editing tool CRISPR-Cas9 to modify wheat gluten, letting people with celiac disease eat gluten without experiencing debilitating symptoms. In celiac disease, the immune system attacks gluten, causing damage to the intestine. This forces sufferers to stick to expensive gluten-free versions of foods such as bread, which […]

January 31, 2019 - 3 minutesmins - By Jonathan Smith

More News! 31 Jan 2019

Novozymes Signs Deal to Develop Biodegradable Plastics

The Danish enzyme manufacturer Novozymes has launched a joint development collaboration with the French biotech Carbios to commercialize biodegradable plastics. Under the agreement, Novozymes is to use its manufacturing muscle to scale up and produce Carbios’ plastic-degrading enzyme technology for Carbios’ subsidiary company Carbiolice. Carbiolice is to embed these enzymes into single-use plastics, such as […]

January 31, 2019 - 2 minutesmins - By Jonathan Smith

orphazyme niemann pick type c disease rare metabolic disease molecules

News and Trends 30 Jan 2019

Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial

A drug, developed by the Danish biotech Orphazyme for a rare metabolic disease, has shown promising results in a phase II/III trial, reducing the disease’s progression by 74%. The 50 patients recruited into the trial suffered from Niemann-Pick disease type C, a metabolic disease in which proteins crucial for storing fat molecules such as cholesterol […]

January 30, 2019 - 3 minutesmins - By Jonathan Smith

Expert Advice 30 Jan 2019

Life Science Email Marketing Best Practices on a Limited Budget

Email marketing is almost as old as the internet itself, and it’s just as relevant to modern businesses. To be in possession of someone’s email (especially when they want you to have it), means you have a direct line to their mind. Every economically active demographic uses email. Despite every kind of challenge […]

January 30, 2019 - 8 minutesmins - By James Mathison

destiny pharma mrsa antibiotic resistance

More News! 29 Jan 2019

Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I

An antibiotic nasal gel, developed by the UK company Destiny Pharma to treat drug-resistant bacterial infections, has shown no adverse effects in healthy volunteers in a phase I trial. Destiny’s antibiotic nasal gel is designed to prevent post-surgical infections of the bacterial species Staphylococcus aureus, which can come in the dangerous drug-resistant strain MRSA. “About […]

January 29, 2019 - 3 minutesmins - By Jonathan Smith

UK Policy Antimicrobial Resistance Biotech

News and Trends 28 Jan 2019

New UK Policy Benefits Biotechs Waging War on Superbugs

Among other measures, the new policy changes the way companies are reimbursed for antimicrobial drugs, which is expected to increase investment in biotech and the interest of big pharma in tackling antimicrobial resistance. Antimicrobial resistance is a huge problem. More and more pathogens are becoming resistant to antibiotics, as seen in the rising number of […]

January 28, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

British Biotech Spin-Offs Get €40M Funding to Treat Narcolepsy

Combo of Immunotherapy and Diabetes Drug Could Beat Breast Cancer

Engineered Chicken Eggs: The Future of Cheap Drug Production?

Swedish Biotech Receives EU Grant for High-Accuracy Kidney Cancer Test

This Biotech Links the Gut Microbiome to Diseases Using Norwegian Poo

Watch Strap Made of Recombinant Spider Silk Launches in Europe

CRISPR Gene Editing Could Make Gluten Safe for Celiacs

Novozymes Signs Deal to Develop Biodegradable Plastics

Danish Biotech’s Drug for Rare Metabolic Disease Aces Clinical Trial

Life Science Email Marketing Best Practices on a Limited Budget

Antibiotic Nasal Gel for Surgical Infections Cruises Through Phase I

New UK Policy Benefits Biotechs Waging War on Superbugs

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!